Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry

Francesco Saladini(University of Siena), Antonella Castagna(Vita-Salute San Raffaele University)

International Journal of Antimicrobial Agents

January 25, 2023

10.1016/j.ijantimicag.2023.106737

Cited by 6

Related Papers

Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency

|Critical Care and Resuscitation|2020|229

Mpox in people with past infection or a complete vaccination course: a global case series

|The Lancet Infectious Diseases|2023|141

Agreement between an in‐house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to <scp>HIV</scp>‐1 protease, reverse transcriptase, and integrase inhibitors

|Journal of Clinical Laboratory Analysis|2017|26

Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors

|BMJ Open|2024|21

One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART Study

|Open Forum Infectious Diseases|2024|20